MacroGenics Expands Board to Eleven Members With Two New Independent Directors
On October 30, 2026, MacroGenics increased its Board from ten to eleven members and appointed Michael Vasconcelles and Emil Kuriakose as independent directors, effective that day. Both were also placed on the Science and Technology Committee and will receive director compensation, including initial option and restricted stock unit awards, which adds modest equity dilution for shareholders. The filing reports no financial results.
Key points
- Board size increased from ten to eleven members, approved October 30, 2026.
- Michael Vasconcelles named Class II Director and Emil Kuriakose named Class III Director, effective October 30, 2026.
- Each director receives an option for 44,000 shares and a restricted stock unit grant for 7,500 shares under the 2023 Equity Incentive Plan.
- Both directors were determined to be independent and joined the Science and Technology Committee.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.